CLINICAL TRIALS PROFILE FOR SAVELLA

All Clinical Trials for SAVELLA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01038323 ↗	Drug and Talk Therapy for Fibromyalgia	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 4	2009-12-01	Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and societal costs in terms of quality of life, social and work functioning, health care use, and lost productivity. Although single therapy approaches such as medication, graduated exercise, and Cognitive Behavioral Therapy (CBT) are well-established treatment approaches, the majority of FMS continue to report significant levels of pain and pain-related disability. Testing the efficacy of using combination therapies such and CBT with medication has considerable potential to maximize treatment response. Also, exploring the biological and psychological mechanisms underlying combination treatment may pave the way for developing new treatments for FMS sufferers. We chose to study drug and CBT for several reasons: 1) the scarcity of trials that manipulate medications along with CBT in FMS, 2) the prohibitive nature of adding an exercise treatment arm in a study that has both time and budgetary constraints, 3) the complexity in understanding the mechanism of actions of 3 different modes of intervention in one clinical trial, and 4) the desire to explore mechanisms in this program of research, in particular the potential effects of a biological intervention (drug) on what is traditionally considered a psychological outcome (pain-related attributions and cognition) and the potential effects of a psychological intervention (CBT) on what is traditionally considered a physiological outcome (pain sensitivity).
NCT01038323 ↗	Drug and Talk Therapy for Fibromyalgia	Completed	Indiana University	Phase 4	2009-12-01	Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and societal costs in terms of quality of life, social and work functioning, health care use, and lost productivity. Although single therapy approaches such as medication, graduated exercise, and Cognitive Behavioral Therapy (CBT) are well-established treatment approaches, the majority of FMS continue to report significant levels of pain and pain-related disability. Testing the efficacy of using combination therapies such and CBT with medication has considerable potential to maximize treatment response. Also, exploring the biological and psychological mechanisms underlying combination treatment may pave the way for developing new treatments for FMS sufferers. We chose to study drug and CBT for several reasons: 1) the scarcity of trials that manipulate medications along with CBT in FMS, 2) the prohibitive nature of adding an exercise treatment arm in a study that has both time and budgetary constraints, 3) the complexity in understanding the mechanism of actions of 3 different modes of intervention in one clinical trial, and 4) the desire to explore mechanisms in this program of research, in particular the potential effects of a biological intervention (drug) on what is traditionally considered a psychological outcome (pain-related attributions and cognition) and the potential effects of a psychological intervention (CBT) on what is traditionally considered a physiological outcome (pain sensitivity).
NCT01077375 ↗	Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia	Completed	Cypress Bioscience, Inc.	Phase 4	2010-02-01	The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.

Clinical Trial Conditions for SAVELLA

Condition Name

Condition Name for SAVELLA
Intervention	Trials
Fibromyalgia	11
Chronic Pain	3
Post Treatment Lyme Syndrome (PTLS)	2

Condition MeSH

Condition MeSH for SAVELLA
Intervention	Trials
Myofascial Pain Syndromes	12
Fibromyalgia	12
Syndrome	4

Clinical Trial Locations for SAVELLA

Trials by Country

Trials by Country for SAVELLA
Location	Trials
United States	63
Canada	1

Trials by US State

Trials by US State for SAVELLA
Location	Trials
New York	7
North Carolina	5
California	5
Florida	4
Ohio	3

Clinical Trial Progress for SAVELLA

Clinical Trial Phase

Clinical Trial Phase for SAVELLA
Clinical Trial Phase	Trials
Phase 4	15
Phase 3	5
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for SAVELLA
Clinical Trial Phase	Trials
Completed	18
Terminated	6
Withdrawn	2

Clinical Trial Sponsors for SAVELLA

Sponsor Name

Sponsor Name for SAVELLA
Sponsor	Trials
Forest Laboratories	21
Duke University	3
New York State Psychiatric Institute	2

Sponsor Type

Sponsor Type for SAVELLA
Sponsor	Trials
Other	29
Industry	25
U.S. Fed	2

Last updated: April 26, 2026

Savella (milnacipran): Clinical Trials Update, Market Analysis, and Projections

What is Savella and what product forms drive the value?

Savella is the brand name for milnacipran, an oral serotonin-norepinephrine reuptake inhibitor (SNRI). The drug is approved for fibromyalgia in the US and other markets, typically in immediate-release tablets (brand formulations vary by jurisdiction).

Core label use

• Indication: Fibromyalgia
• Class: SNRI
• Mechanism: Inhibits serotonin and norepinephrine reuptake (milnacipran)

Commercial implication

• Revenue is concentrated in the fibromyalgia category and is sensitive to (1) competing SNRI use, (2) access and payer policies, and (3) generic entry risk in each geography.

---

What is the clinical-trials status for Savella?

As a marketed small molecule with long-standing approval, Savella’s clinical-trial footprint typically shifts from “new-to-brand” studies to:

• post-marketing safety or adherence studies,
• label-support work,
• formulation or exposure-management studies,
• comparative effectiveness and real-world evidence.

Key pattern to track

• Milnacipran is not generally positioned as an innovative late-stage pipeline asset versus newer fibromyalgia-specific candidates. The highest-likelihood “trial updates” are incremental design changes rather than new indications.

Practical due diligence focus

• Trial databases often surface a mix of active, recruiting, completed, and terminated studies across geographies.
• For investment and competitive positioning, prioritize:
  • trials with novel endpoints (pain/function, responder thresholds),
  • studies that recruit in major payer geographies,
  • head-to-head designs against accepted fibromyalgia SOC comparators.

No complete, verified trial-by-trial dataset is included here because the request requires accuracy across “clinical trials update” and projections, and no trial register snapshots were provided in the prompt.

---

How does the fibromyalgia market shape Savella demand?

Fibromyalgia remains a chronic pain category where treatment often blends:

• SNRIs and other antidepressant-like agents,
• gabapentinoids,
• nonpharmacologic management,
• limited use of newer agents depending on regional approvals and reimbursement.

Demand drivers

• Chronic, relapsing course supports ongoing prescribing.
• Payer controls and formulary status determine persistence.
• Side-effect tolerability affects adherence.

Competitive dynamics Savella competes within SNRI and broader neuropathic pain pharmacotherapy:

• Other SNRIs used off-label or on-label depending on jurisdiction
• Generic penetration pressure where patent life has expired and where generic milnacipran is available and covered

Market risk

• Milnacipran’s brand economics depend heavily on:
  • generic entry timing by country,
  • uptake of generics versus brand loyalty,
  • prescribing behavior shifts to newer agents where they exist.

---

What is the market projection range for milnacipran/Savella?

A credible projection requires country-level revenue baselines, generic share assumptions, price erosion schedules, and payer coverage. Those elements were not provided in the prompt and cannot be derived without verified sources.

Projection framework used by market teams (inputs needed for accuracy)

• Baseline brand sales by geography (US, EU5, other major markets)
• Milnacipran generic status and entry dates by jurisdiction
• Price erosion curve by time since generic launch
• Formulary access changes (preferred vs non-preferred)
• Uptake of competing therapies in fibromyalgia
• Share shift due to safety/tolerability and guideline updates

No quantified projection is included here because a complete and accurate market model cannot be produced from the prompt alone.

---

What could change near-term: catalyst map for Savella?

In established branded SNRI franchises, near-term catalysts typically fall into one of two bins:

1. Regulatory/label events

   • Changes in dosing, safety communications, or inclusion in guideline-relevant frameworks

2. Competitive and market-access events

   • Generic price compression and formulary exclusion
   • Changes in payer restrictions for fibromyalgia drug classes

Business takeaway

• For long-cycle brands, the most decisive “catalysts” are usually commercial: generic entry, formulary status, and payer steering rather than new efficacy milestones.

---

Key Takeaways

• Savella (milnacipran) is a long-standing oral SNRI for fibromyalgia; its revenue engine depends on chronic use and payer access rather than late-stage innovation.
• The clinical-trial “update” track for milnacipran is generally incremental (post-marketing, comparative, or real-world/label-support work) rather than disruptive new indications.
• A high-accuracy market projection requires verified baseline sales and jurisdiction-level generic and payer assumptions; those inputs are not present in the prompt, so no quantified projection is provided.

---

FAQs

1) Is Savella still actively studied in clinical trials?

Milnacipran studies typically continue through post-marketing and comparative/real-world programs rather than major new indication development, but a definitive trial-by-trial status requires a verified trial register snapshot.

2) What drives Savella revenue most strongly?

Fibromyalgia patient volume, persistence (adherence), and formulary position drive brand performance; generic penetration and payer restrictions determine downside risk.

3) What is the main competitive threat to Savella?

Generic milnacipran price compression in markets where generics are available, plus therapeutic substitution within fibromyalgia pharmacotherapy.

4) Do label expansions materially improve Savella market potential?

Material expansion is uncommon for established branded assets; most value changes come from access and class positioning rather than new approvals.

5) How should an investor model downside for Savella?

Model a combined scenario of price erosion, generic share capture, and payer steering away from non-preferred products, then apply to geography-specific baseline sales.

---

References

[1] FDA. Prescribing information for Savella (milnacipran) (US).
[2] EMA. Product information and assessment documents for milnacipran where applicable.
[3] ClinicalTrials.gov. Milnacipran studies registry (search results and study records for milnacipran/Savella).
[4] FDA. Drug approvals and labeling history for milnacipran (Savella).